Are you Dr. Matin?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 91 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-794-4824- Is this information wrong?
Summary
- Dr. Surena Matin, MD is a board certified urologist in Houston, Texas. He is currently licensed to practice medicine in Texas, Alabama, and Tennessee. He is affiliated with University of Texas M.D. Anderson Cancer Center and is a Professor at Division of Surgery.
Education & Training
- Cleveland Clinic FoundationResidency, Urology, 1994 - 2000
- Weill Cornell MedicineClass of 1994
Certifications & Licensure
- FL State Medical License 2021 - Present
- TX State Medical License 2002 - 2025
- GA State Medical License 2023 - 2025
- AL State Medical License 2023 - 2024
- TN State Medical License 2023 - 2024
- AZ State Medical License 2023 - 2024
- OK State Medical License 2020 - 2024
- American Board of Urology Urology
- Join now to see all
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer Start of enrollment: 2020 Jul 28
Publications & Presentations
PubMed
- YIA24-001: Spatial Evolution of Immune Cell Dysfunction During Development of Oligometastatic Renal Cell Carcinoma: Secondary Analysis of a Prospective Trial.Chad Tang, Kieko Hara, Alexander D Sherry, Alejandra G Serrano, Larisa V Kostousov, Sharia D Hernandez, Wei Lu, Li Shen, Amishi Y Shah, Eric Jonasch, Jose A Karam, Sur...> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
- Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma.Rhenita Amirtharaj, Lianchun Xiao, Dzifa Y Duose, Shufang Wang, Surena F Matin, Mehrad Adibi, Amishi Y Shah, Omar Alhalabi, Paul Corn, Charles Guo, Suzanne Lange, Suma...> ;The Journal of Urology. 2024 Apr 10
- Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial.Sumanta K Pal, Petros Grivas, Shilpa Gupta, Nazli Dizman, Zeynep Zengin, Begona P Valderrama, Alejo Rodriguez-Vida, Florian Roghmann, Elena Sevillano Fernandez, Surena...> ;European Urology. 2024 Apr 4
- Join now to see all
Press Mentions
- How I Turned My Kidney and Brain Cancer Diagnoses into Something MeaningfulMay 29th, 2019
- Telemedicine Extends Minimally Invasive Surgery’s BenefitsJanuary 13th, 2016
- ASCO GU 2020: Upper Tract Disease: Topical Therapy, Systemic TherapyFebruary 17th, 2020
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
- University of Texas M.D. Anderson Cancer CenterHouston, Texas